Zepbound (tirzepatide) 10 mg/0.5 mL – Complete Guide
🔹 Key Details
-
Dosage: 10 mg per 0.5 mL (4th step in titration, after 2.5 mg → 5 mg → 7.5 mg).
-
Administration: Subcutaneous (under skin) once weekly via pre-filled auto-injector.
-
FDA Approval: For chronic weight management in adults with:
-
BMI ≥30 kg/m² (obesity) OR
-
BMI ≥27 kg/m² + weight-related condition (e.g., hypertension, type 2 diabetes).
-
🔹 Dosing Schedule
| Weeks | Dose | Purpose |
|---|---|---|
| 1–4 | 2.5 mg | Starter (minimizes side effects) |
| 5–8 | 5 mg | Initial therapeutic dose |
| 9–12 | 7.5 mg | Intermediate dose |
| 13+ | 10 mg | Higher efficacy (may increase further to 12.5 mg or 15 mg if needed) |
Note: Some patients stay at 10 mg if achieving sufficient weight loss with minimal side effects.
🔹 Effectiveness
-
Clinical Trial Data (SURMOUNT-1):
-
10 mg dose: Average weight loss of ~18–21% over 72 weeks (with diet/exercise).
-
15 mg dose: Up to 22.5% weight loss (highest dose).
-
-
Comparison to Wegovy (semaglutide):
-
Zepbound (dual GLP-1/GIP agonist) may lead to ~2–5% greater weight loss than Wegovy (GLP-1 only).
-
🔹 Side Effects
| Common (≥10%) | Less Common (1–10%) | Rare but Serious |
|---|---|---|
| Nausea, diarrhea, constipation, vomiting | Fatigue, dizziness, heartburn | Pancreatitis, gallbladder disease, kidney inj |
Reviews
There are no reviews yet.